Last reviewed · How we verify
NCT05301296: TBCS
Trivandrum Breast Cancer Screening Trial
NA trial testing Clinical examination of the breast for early detection of Cancer in Breast Cancer in 115,290 participants. Completed in 31 December 2019.
31 December 2014
Quick facts
| Lead sponsor | International Agency for Research on Cancer |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 115,290 |
| Start date | 1 January 2006 |
| Primary completion | 31 December 2014 |
| Estimated completion | 31 December 2019 |
Drugs / interventions tested
- Clinical examination of the breast for early detection of Cancer
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
International Agency for Research on Cancer
Who can join
Adults 30 to 69, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cluster-randomized controlled trial in Trivandrum district, Kerala, India to evaluate the effect of triennial screening for breast cancer using clinical breast examination on breast cancer mortality.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.
Ramadas K, Basu P, Mathew BS, Muwonge R, et al · · 2023 · cited 19× · PMID 36321193 · DOI 10.1002/cncr.34526
Verify or expand the search:
- PubMed search for NCT05301296
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other International Agency for Research on Cancer trials
Trials by the same sponsor.
- NCT07256912 — A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared t · Phase 4 · not yet recruiting
- NCT07193030 — Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania · NA · not yet recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT06749847 — HPV Self-sampling in the General Population · NA · recruiting
- NCT07407153 — Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05301296 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Agency for Research on Cancer
- Last refreshed: 29 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05301296.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing